Table 1.
Studies included in the systematic review and meta-analysis.
| Included in systematic review (N = 69) (n, %) | Included in PP-IFI meta-analysis (N = 20) (n, %) | Included in PPP-IFI meta-analysis (N = 36) (n, %) | |
|---|---|---|---|
| Total number of patients | 33 968 | 6 334 | 9 744 |
| Total number of episodes | 35 781 | 7 261 | 11 247 |
| Total number of IFI episodes | 2917 | 744 | 1 348 |
| Study period | |||
| Beginning study period (year, IQR1-3, range) | 2008 (2004–2012, 1995–2017) | 2009 (2004–2012, 2000–2017) | 2005 (2002–2011, 1996–2017) |
| End study period (year, IQR1-3, range) | 2015.5 (2011–2019, 2000–2022) | 2016 (2013-2018.5, 2006–2020) | 2014 (2010.5–2018, 2000–2020) |
| Study type | |||
| Cohort | 63 (91) | 20 (100) | 35 (97) |
| Prospective | 6 (10) | 3 (15) | 4 (11) |
| Retrospective | 57 (90) | 17 (85) | 32 (89) |
| Case-control study | 6 (9) | 0 (0) | 1 (3) |
| Centers | |||
| Single-center | 56 (81) | 16 (80) | 30 (83) |
| Multicenter | 13 (19) | 4 (20) | 6 (17) |
| Type of definition of IFI | |||
| EORTC/MSG 20026 | 4 (6) | 0 (0) | 2 (6) |
| EORTC/MSG 20087 | 49 (71) | 17 (85) | 30 (82) |
| EORTC/MSG 20208 | 13 (19) | 3 (15) | 4 (12) |
| Other definition or not specified | 3 (4) | 0 (0) | 0 (0) |
| Continent | |||
| North America | 24 (35) | 5 (25) | 10 (28) |
| Asiaa | 23 (33) | 8 (40) | 14 (38) |
| Europe | 18 (26) | 6 (30) | 10 (28) |
| South America | 2 (3) | 1 (5) | 2 (6) |
| Oceania | 2 (3) | 0 (0) | 0 (0) |
| Population | |||
| Adults only | 60 (87) | 18 (90) | 29 (80) |
| ≥ 90% adults | 9 (13) | 2 (10) | 7 (20) |
| Hematological malignancies | 42 (61) | 12 (60) | 21 (58) |
| Hematological malignancy, any type | 9 (14) | 1 (5) | 3 (8) |
| Lymphoproliferative disorder | 10 (14) | 2 (10) | 4 (11) |
| Myeloid malignancy | 18 (26) | 6 (30) | 9 (25) |
| Otherb | 5 (7) | 3 (15) | 5 (14) |
| HSCT | 27 (39) | 8 (40) | 15 (42) |
| HSCT, any type | 5 (7) | 1 (5) | 3 (8) |
| Allo-HSCT | 20 (29) | 7 (35) | 11 (31) |
| Auto-HSCT | 2 (3) | 0 (0) | 1 (3) |
ALL acute lymphoid leukemia; AML acute myeloid leukemia; HSCT hematogenous stem cell transplant; IFI invasive fungal infection; IQR interquartile range; MDS myelodysplastic syndrome; PP proven and/or probable; PPP proven, probable and/or possible.
aIn the systematic review, 2 of the included studies took place in Turkey and were counted in the Asia continent.
bIn the systematic review, other hemopathies were: acute leukemia (n = 2), ALL/AML, acute leukemia and MDS in transformation, hematological patients; In the PP-IFI meta-analysis, other hemopathies were : acute leukemia, ALL/AML, acute leukemia and MDS in transformation; in the PPP-IFI meta-analysis, other hemopathies were: acute leukemia and MDS in transformation, hematological patients, acute leukemia (n = 2), ALL/AML.